Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen Academic Article uri icon


MeSH Major

  • Leukemia
  • Receptors, Antigen, T-Cell
  • WT1 Proteins


  • CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set of leukemia patients. However, CAR T-cell therapy thus far has been largely restricted to targeting extracellular tumor-associated antigens (TAA). Herein, we report a T-cell receptor-mimic (TCRm) CAR, termed WT1-28z, that is reactive to a peptide portion of the intracellular onco-protein Wilms Tumor 1(WT1), as it is expressed on the surface of the tumor cell in the context of HLA-A*02:01. T cells modified to express WT1-28z specifically targeted and lysed HLA-A*02:01+ WT1+ tumors and enhanced survival of mice engrafted with HLA-A*02:01+, WT1+ leukemia or ovarian tumors. This in vivo functional validation of TCRm CAR T cells provides the proof-of-concept necessary to expand the range of TAA that can be effectively targeted for immunotherapy to include attractive intracellular targets, and may hold great potential to expand on the success of CAR T-cell therapy.Leukemia advance online publication, 3 January 2017; doi:10.1038/leu.2016.373.

publication date

  • January 3, 2017



  • Academic Article



  • eng

PubMed Central ID

  • PMC5495623

Digital Object Identifier (DOI)

  • 10.1038/leu.2016.373

PubMed ID

  • 27924074

Additional Document Info